ARID1A and in situ carcinoma: As current ARID1A protein expression data for bladder cancer are inconsistent and incomplete, a comprehensive immunohistochemistry (IHC)-based ARID1A protein expression analysis including carcinoma in situ (CIS) cases was conducted for the first time.